IP Library Granted Patent US 10,166,228
Granted Patent B2
US 10,166,228 · App. 15/961,201 · Granted Jan 1, 2019

Polymorphic forms of naltrexone

Inventors: Harry G. Brittain (Milford, NJ); David A. Dickason (Cincinnati, OH); Joyce M. Hotz (Cincinnati, OH); Shawn L. Lyons (Cincinnati, OH); J. Michael Ramstack (Lunenburg, MA); Steven G. Wright (Madeira, OH)
Assignee: Alkermes Pharma Ireland Limited
A61K31/485C07C19/03C07D489/06C07D489/08C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,228
App. No.
15/961,201
Granted
Jan 1, 2019
Kind
B2
Abstract

This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.

Claims (10)

1. A polymorphic form of naltrexone hexane solvate which is characterized by at least one of:

(a) the X-ray powder diffraction pattern of FIG. 12A ;

(b) the differential scanning calorimetry thermogram of FIG. 24A ; and

(c) the IR-ATR spectrum of FIG. 36A .

2. A pharmaceutical composition comprising the polymorphic form according to claim 1 and a pharmaceutically acceptable carrier.

3. A polymorphic form of naltrexone hexane solvate which is characterized by at least one of:

(a) the X-ray powder diffraction pattern of FIG. 12B ;

(b) the differential scanning calorimetry thermogram of FIG. 24B ; and

(c) the IR-ATR spectrum of FIG. 36B .

4. A pharmaceutical composition comprising the polymorphic form according to claim 3 and a pharmaceutically acceptable carrier.

Assignments (1)
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
Continuity (11)
Continuation 15794365 · Oct 26, 2017
Continuation 15381581 · Dec 16, 2016
Continuation 15175399 · Jun 7, 2016
Continuation 14945607 · Nov 19, 2015
Continuation 14612904 · Feb 3, 2015
Continuation 14249613 · Apr 10, 2014
Continuation 13690327 · Nov 30, 2012
Continuation 11960677 · Sep 25, 2007
Division 10860608 · Jun 3, 2004
Provisional Application 60475863 · Jun 4, 2003
Related Publication 20180303825A1 · Oct 25, 2018
Cited By (2)
US 12,303,604 US 12,599,563